Please login to the form below

Not currently logged in

Conflicts of interest

This page shows the latest Conflicts of interest news and features for those working in and with pharma, biotech and healthcare.

Someone like you

Someone like you

Most of the mainstream information on the role of patient influencers focuses on the inherent conflicts of interest, whether this activity transgresses the tight rules around direct-to-consumer advertising and, ... Rarely do we discuss the policy/public

Latest news

  • Nearly half of HCPs refuse to disclose pharma payments Nearly half of HCPs refuse to disclose pharma payments

    in its latest six-month 'snapshot', of which £254m was spent on R&D. ... We will continue to work with the NHS, particularly in the light of their new conflicts of interest guidance which advocates disclosing on our database, to make this a reality.

  • EMA to stop ‘revolving doors’ committee members EMA to stop ‘revolving doors’ committee members

    The effective management of conflicts of interests is key to ensuring the independence and integrity of the Agency's scientific recommendations.”. ... On the back of his departure the EMA was in hit by a barrage of criticism from the European

  • Counting value under the US Sunshine Act Counting value under the US Sunshine Act

    International in scope, the implication of the transparency legislation are anything but clear. ... Either way, it is important to keep sight of the benefits of transparency in avoiding conflicts of interest and helping companies to be more efficient in

  • US CROs to report payments to physicians

    The ruling, released last week, also applies to both CMOs and CROs and will cover"payments and transfers of value", including consulting fees, honoraria, gifts, travel and entertainment. ... The intent of this law is to bring potential conflicts of

  • Pharma's engagement with patient groups

    evidence:. The research organisation PatientView estimates that millions of patient groups exist worldwide. ... A company record of managing conflicts of interest in relations with patient groups.

More from news
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Managing misconduct allegations Managing misconduct allegations

    Potential internal candidates may include non-executive directors, members of the legal department or compliance. ... Relevant considerations include their involvement in the underlying issues and their independence and ability to manage conflicts of

  • Stress testing for the perfect compliance storm Stress testing for the perfect compliance storm

    In addition, 38% of respondents in this sector could justify unethical behaviour to meet financial targets. ... For example, in Europe, increased transparency requirements are making perceived and actual conflicts of interest more visible - placing a

  • Could EFPIA's new code boost pharma's reputation? Could EFPIA's new code boost pharma's reputation?

    but all of this can be tainted by a suspicion over our payments to HCPs. ... But here is where the perceived conflicts of interest lay. “Now, for several years we've been looking at creating a sustainable business model to address these perceived

  • The changing regulatory environment The changing regulatory environment

    EFPIA recognises that interactions between the industry and healthcare professionals can create the potential for conflicts of interest. ... The mechanism of disclosure, at the time of writing, has not yet been determined.

  • Revamping the NHS and the challenges for pharma Revamping the NHS and the challenges for pharma

    It therefore recommended that GPs with expensive prescribing habits should be required to explain their decisions to their CCG – hence potentially creating conflicts between CCGs and pharmaceutical companies. ... GPs are also becoming more aware of

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...